Mirzayeva Nurlana, Forst Susanne, Passweg Daniel, Geissbühler Verena, Simões-Wüst Ana Paula, Betschart Cornelia
Department of Gynaecology, University Hospital and University Zurich, Zurich 8091, Switzerland.
Department of Obstetrics and Gynaecology, Cantonal Hospital Aarau, Aarau 5001, Switzerland.
Evid Based Complement Alternat Med. 2023 Feb 7;2023:2115335. doi: 10.1155/2023/2115335. eCollection 2023.
Nocturia is a pathologic condition that significantly affects the quality of sleep. The aetiology of nocturia is multifactorial, and the evidence available on its management remains limited. Besides behavioural measures, validated pharmaceutical treatment options exist but are, however, associated with marked side effects. Prospective clinical studies with tablets prepared from the leaf press juice of the plant revealed a tendency towards reduction of micturition in patients with overactive bladder (OAB) and several improvements in sleep quality. These observations are in part supported by in vitro and in vivo data. In the present study, we investigated the effectiveness of Bryophyllum 50% chewable tablets in the treatment of nocturia and associated sleep disorders. Altogether, 49 women with idiopathic OAB and nocturia of ≥2 voids/night were treated with Bryophyllum 50% tablets for 3 weeks (350 mg chewable tablets, dosage 0-0-2-2 oral tablets; WELEDA AG, Arlesheim, Switzerland). Nocturia, voiding volumes at night (ml), quality of life, sleep quality, and daily sleepiness were assessed before and after treatment with a 3-day micturition diary, the International Consultation on Incontinence evaluating overactive bladder and related impact on quality of life (QoL) [ICIQ-OAB], the Pittsburgh Sleep Quality Index (PSQI), and the Epworth Sleepiness Scale (ESS), respectively. The age of the study population was 68.5 ± 11.6 y. After treatment, nocturia diminished from 3.2 ± 1.4 to 2.3 ± 1.3 ( < 0.001) and the PSQI score decreased from 7.7 ± 3.7 to 6.6 ± 3.4 (=0.004). Urgency, the ICIQ score, and the ESS lowered significantly, and the micturition volume showed a tendency to increase. No serious adverse drug reactions were reported, and compliance was good. The results show a beneficial effect on the nocturnal voids and sleep quality of women with OAB. Bryophyllum 50% tablets can be regarded as a well-tolerated alternative in the treatment of nocturia and broaden the repertoire of standard management.
夜尿症是一种严重影响睡眠质量的病理状况。夜尿症的病因是多因素的，关于其治疗的现有证据仍然有限。除了行为措施外，虽然存在经过验证的药物治疗选择，但却伴有明显的副作用。对用该植物压榨叶汁制成的片剂开展的前瞻性临床研究显示，膀胱过度活动症（OAB）患者的排尿次数有减少趋势，睡眠质量也有多项改善。这些观察结果在一定程度上得到了体外和体内数据的支持。在本研究中，我们调查了50%落地生根咀嚼片治疗夜尿症及相关睡眠障碍的有效性。共有49名患有特发性OAB且夜尿次数≥每晚2次的女性接受了50%落地生根片剂治疗3周（350毫克咀嚼片，剂量为0 - 0 - 2 - 2口服片；瑞士阿尔莱斯海姆的维蕾德股份公司）。在治疗前后，分别使用3天排尿日记、评估膀胱过度活动症及对生活质量（QoL）相关影响的国际尿失禁咨询委员会[ICIQ - OAB]、匹兹堡睡眠质量指数（PSQI）和爱泼华嗜睡量表（ESS），对夜尿症、夜间排尿量（毫升）、生活质量、睡眠质量和每日嗜睡情况进行了评估。研究人群的年龄为68.5±11.6岁。治疗后，夜尿次数从3.2±1.4次减少至2.3±1.3次（<0.001），PSQI评分从7.7±3.7降至6.6±3.4（=0.004）。尿急、ICIQ评分和ESS显著降低，排尿量有增加趋势。未报告严重药物不良反应，依从性良好。结果显示对OAB女性的夜间排尿和睡眠质量有有益影响。50%落地生根片剂可被视为治疗夜尿症耐受性良好的替代方法，拓宽了标准治疗方法的范围。
